EpiAxis Therapeutics Announces Positive Clinical Trial Data for its New Drug Program to Inhibit Metastatic Breast Cancer

EpiAxis Therapeutics has announced a pioneering clinical study, showing that an epigenetic inhibitor combined with chemotherapy can treat metastatic cancer.

Related Keywords

Australia ,Japan ,Syderstone ,Norfolk ,United Kingdom ,United States ,New Jersey ,Sydney ,New South Wales ,Israel ,Canberra ,Australian Capital Territory ,Australian ,Sudha Rao ,Jeremy Chrisp ,Wayne Pambianchi ,Canberra Region Cancer Centre ,Southern Medical Day Care Centre ,Sage Group ,International Convention ,Sage Group Inc ,San Diego Convention Center ,Epiaxis Therapeutics ,Axis Therapeutics ,Liverpool Hospital ,Professor Sudha ,Epiaxis ,Therapeutics ,Announces ,Positive ,Clinical ,Trial ,Data ,For ,Its ,New ,Drug ,Program ,To ,Inhibit ,Metastatic ,Breast ,Cancer ,